title: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
abstract: OBJECTIVE
  To assess the efficacy of gemcitabine in patients with a variety of sarcomas that have failed to respond or escaped Adriamycin- and ifosfamide-based chemotherapy.
  
  
  METHODS
  A group of 18 symptomatic heavily pretreated patients with sarcomas of bone or soft tissue received one induction course of gemcitabine at a dose of 1000 mg/m(2) per week for 7 consecutive weeks, followed by 1 week rest. Response to the induction course was assessed by interview and by repeated ancillary tests. If no progression was observed, maintenance by gemcitabine 1000 mg/m(2) per week for 3 weeks every 28 days was given until failure was clinically or radiologically evident.
  
  
  RESULTS
  A total of 51 cycles of gemcitabine were given including 18 cycles of induction. A mean of 3.6 postinduction cycles were given to nine patients. The treatment was well tolerated by the patients. One partial response (leiomyosarcoma) and one minimal response (angiosarcoma) were observed, yielding a true objective response rate of 5.5%. An additional six patients achieved stabilization of disease (chondrosarcoma and osteosarcoma), yielding an overall progression-free rate of 44%. The median time to progression was more than 27 weeks. Clinical benefit response was observed only in those who also achieved a progression-free state.
  
  
  CONCLUSIONS
  Gemcitabine was found to be effective in achieving stabilization and even a minimal response of soft tissue or bone sarcoma refractory to standard chemotherapy.
authors.affiliation: Department of Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. merimsky@internet-zahav.net
authors.forename: O
authors.initials: O
authors.lastname: Merimsky
authors.forename: I
authors.initials: I
authors.lastname: Meller
authors.forename: G
authors.initials: G
authors.lastname: Flusser
authors.forename: Y
authors.initials: Y
authors.lastname: Kollender
authors.forename: J
authors.initials: J
authors.lastname: Issakov
authors.forename: M
authors.initials: M
authors.lastname: Weil-Ben-Arush
authors.forename: E
authors.initials: E
authors.lastname: Fenig
authors.forename: G
authors.initials: G
authors.lastname: Neuman
authors.forename: D
authors.initials: D
authors.lastname: Sapir
authors.forename: S
authors.initials: S
authors.lastname: Ariad
authors.forename: M
authors.initials: M
authors.lastname: Inbar
mesh_terms: D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002813:Chondrosarcoma / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine